Ubs Group Ag Relmada Therapeutics, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 144,789 shares of RLMD stock, worth $108,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares

144,789

Previous 215,140 32.7%

Holding current value

$108,591

Previous $111,000 64.86%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$0.26 - $0.47 $18,291 - $33,064	-70,351 Reduced 32.7%	144,789 $39,000
Q4 2024 Feb 14, 2025	BUY	$0.35 - $3.65 $31,064 - $323,955	88,755 Added 70.23%	215,140 $111,000
Q3 2024 Nov 14, 2024	SELL	$2.3 - $4.36 $5,554 - $10,529	-2,415 Reduced 1.88%	126,385 $409,000
Q2 2024 Aug 13, 2024	SELL	$2.93 - $4.94 $1,421 - $2,395	-485 Reduced 0.38%	128,800 $386,000
Q1 2024 May 13, 2024	BUY	$3.1 - $6.8 $11,020 - $24,174	3,555 Added 2.83%	129,285 $601,000
Q4 2023 Feb 09, 2024	BUY	$2.45 - $4.22 $102 - $177	42 Added 0.03%	125,730 $520,000
Q3 2023 Nov 09, 2023	BUY	$2.48 - $3.79 $66,216 - $101,193	26,700 Added 26.97%	125,688 $377,000
Q2 2023 Aug 11, 2023	BUY	$2.22 - $3.54 $216,250 - $344,831	97,410 Added 6173.0%	98,988 $243,000
Q1 2023 May 12, 2023	SELL	$2.24 - $4.76 $9,710 - $20,634	-4,335 Reduced 73.31%	1,578 $3,000
Q4 2022 Feb 08, 2023	SELL	$2.17 - $35.84 $371 - $6,128	-171 Reduced 2.81%	5,913 $20,000
Q3 2022 Nov 10, 2022	BUY	$18.3 - $37.02 $87,034 - $176,067	4,756 Added 358.13%	6,084 $225,000
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $31,249 - $50,444	-1,869 Reduced 58.46%	1,328 $36,000
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $25,767 - $40,820	-1,522 Reduced 32.25%	3,197 $72,000
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $2,142 - $3,407	98 Added 2.12%	4,719 $124,000
Q2 2021 Aug 13, 2021	SELL	$29.55 - $39.15 $56,883 - $75,363	-1,925 Reduced 29.41%	4,621 $148,000
Q1 2021 May 12, 2021	SELL	$31.52 - $39.28 $27,516 - $34,291	-873 Reduced 11.77%	6,546 $230,000
Q4 2020 Feb 11, 2021	BUY	$29.88 - $39.8 $53,933 - $71,839	1,805 Added 32.15%	7,419 $238,000
Q3 2020 Nov 12, 2020	SELL	$34.42 - $43.78 $94,551 - $120,263	-2,747 Reduced 32.85%	5,614 $211,000
Q2 2020 Jul 31, 2020	BUY	$31.59 - $49.98 $167,995 - $265,793	5,318 Added 174.76%	8,361 $374,000
Q1 2020 May 01, 2020	SELL	$23.78 - $50.12 $28,868 - $60,845	-1,214 Reduced 28.52%	3,043 $104,000
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $42,995 - $200,845	4,257 New	4,257 $166,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

6.3M

Call Options Held

Put Options Held

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $21.5M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account